A New Wave of Progress in the Treatment of Hepatocellular Cancer

home / peer-exchange / a-new-wave-of-progress-in-the-treatment-of-hepatocellular-cancer

Experts in gastrointestinal cancers review recent updates to the treatment landscape of advanced HCC and share insights on their impact on clinical practice.

EP. 1: First-Line Systemic Treatment for Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 9th 2022

Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.

EP. 2: Phase 3 COSMIC-312 Study in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 9th 2022

Daneng Li, MD, evaluates the use of cabozantinib plus atezolizumab in first-line advanced unresectable HCC as seen in the COSMIC-312 study.

EP. 3: Phase 3 HIMALAYA Study in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 16th 2022

Dr Daneng Li reviews updated safety and efficacy results of durvalumab plus tremelimumab from the phase 3 HIMALAYA study in frontline unresectable HCC.

EP. 4: Which Patients With HCC Are Suitable for Treatment With Atezolizumab and Bevacizumab?

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 16th 2022

Nicole Rich, MD, reviews the patient selection for atezolizumab-bevacizumab and discusses patients in whom this regimen is contraindicated in the frontline setting in advanced HCC.

EP. 5: Frontline Therapies in Advanced HCC for Patients Unsuitable for Atezolizumab-Bevacizumab

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 23rd 2022

Pierre Gholam, MD, considers the optimal treatment selection for patients in whom an atezolizumab-bevacizumab combination isn’t a suitable frontline therapeutic option.

EP. 6: Is There a Role for Single-Agent Immunotherapy in Advanced HCC?

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 23rd 2022

Experts in gastrointestinal cancers, Drs Pierre Gholam and Daneng Li, comment on the role of single-agent immunotherapy for first-line treatment of advanced HCC.

EP. 7: Emerging Frontline Treatment Strategies in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 30th 2022

Daneng Li, MD, discusses novel regimens in the pipeline being evaluated for the treatment of frontline advanced HCC.

EP. 8: Is There a Role for Liver-Directed Therapy in Advanced HCC?

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

March 30th 2022

An expert gastroenterologist, Dr Pierre Gholam, discusses the phase 3 LAUNCH trial and shares insight on the potential role of liver-directed therapy in the treatment of advanced hepatocellular carcinoma.

EP. 9: Anti-Angiogenic Therapies in Second-Line and Beyond in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 6th 2022

Anthony B. El-Khoueiry, MD, reviews anti-angiogenic systemic therapy options for patients with advanced HCC in the second-line and beyond setting.

EP. 10: Immunotherapies in Second-Line and Beyond in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 6th 2022

Pierre Gholam, MD, comments on systemic immunotherapy options for second-line and beyond treatment of advanced hepatocellular carcinoma.

EP. 11: Selecting the Appropriate Treatment in Second-Line and Beyond in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 13th 2022

Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.

EP. 12: Sequencing Therapies After Frontline TKI Therapy in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 13th 2022

Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.

EP. 13: Unmet Needs in the Treatment of Advanced HCC in Second-Line and Beyond

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 20th 2022

Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.

EP. 14: How the Potential Use of Immunotherapy in Intermediate HCC Might Affect its Use in Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 20th 2022

Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.

EP. 15: Patient Case: 63-Year-Old Woman With Advanced HCC

By Anthony B. El-Khoueiry, MD
Nicole Rich, MD

April 20th 2022

Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.